iTeos Therapeutics (NASDAQ:ITOS) Price Target Cut to $32.00

iTeos Therapeutics (NASDAQ:ITOS – Get Rating) had its price objective trimmed by JPMorgan Chase & Co. from $34.00 to $32.00 in a report published on Thursday, Benzinga reports. The firm currently has an overweight rating on the stock.

Separately, Wedbush decreased their price target on shares of iTeos Therapeutics from $45.00 to $33.00 and set an outperform rating on the stock in a research note on Thursday.

iTeos Therapeutics Stock Performance

ITOS stock opened at $14.12 on Thursday. The company’s 50-day simple moving average is $18.81 and its 200 day simple moving average is $19.40. iTeos Therapeutics has a 52 week low of $13.81 and a 52 week high of $37.26. The company has a market capitalization of $504.37 million, a PE ratio of 5.49 and a beta of 1.42.

Institutional Investors Weigh In On iTeos Therapeutics

A number of large investors have recently bought and sold shares of the company. State of Tennessee Treasury Department grew its stake in iTeos Therapeutics by 10.4% during the fourth quarter. State of Tennessee Treasury Department now owns 15,560 shares of the company’s stock worth $304,000 after buying an additional 1,468 shares in the last quarter. Legal & General Group Plc grew its stake in iTeos Therapeutics by 2.6% during the fourth quarter. Legal & General Group Plc now owns 59,065 shares of the company’s stock worth $1,154,000 after buying an additional 1,511 shares in the last quarter. Morgan Stanley grew its stake in iTeos Therapeutics by 1.6% during the fourth quarter. Morgan Stanley now owns 846,859 shares of the company’s stock worth $16,539,000 after buying an additional 12,965 shares in the last quarter. Endurant Capital Management LP acquired a new stake in iTeos Therapeutics during the fourth quarter worth about $411,000. Finally, Alps Advisors Inc. lifted its holdings in shares of iTeos Therapeutics by 13.3% in the fourth quarter. Alps Advisors Inc. now owns 39,697 shares of the company’s stock worth $775,000 after acquiring an additional 4,652 shares during the last quarter.

About iTeos Therapeutics

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.